Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jul 18, 2021; 11(7): 303-319
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.303
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.303
Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis
Boonphiphop Boonpheng, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States
Panupong Hansrivijit, Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA 17104, United States
Charat Thongprayoon, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States
Shennen A Mao, Division of Transplant Surgery, Mayo Clinic, Jacksonville, FL 32224, United States
Pradeep K Vaitla, Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, United States
Tarun Bathini, Department of Internal Medicine, University of Arizona, Tucson, AZ 85721, United States
Avishek Choudhury, School of Systems and Enterprises, Stevens Institute of Technology, Hoboken, NJ 07030, United States
Wisit Kaewput, Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand
Michael A Mao, Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL 32224, United States
Wisit Cheungpasitporn, Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States
Author contributions: Boonpheng B performed the conceptualization, data curation, formal analysis, investigation, methodology, software, validation, visualization, preparation of original draft, review and editing of manuscript; Hansrivijit P performed the conceptualization, data curation, investigation, visualization, review and editing of manuscript; Thongprayoon C performed the conceptualization, supervision, visualization, review and editing of manuscript; Mao SA supervision, visualization, review and editing of manuscript; Vaitla PK, Bathini T, Mao MA, and Choudhury A performed the project administration; Bathini T, Kaewput W, and Choudhury A performed the project resources; Vaitla PK, Bathini T, Mao MA, Choudhury A, and Kaewput W performed the project supervision, review and editing of manuscript; Mao MA performed the conceptualization; Cheungpasitporn W conceptualization, investigation, methodology, supervision, validation, visualization, review and editing of manuscript; all authors had access to the data, and played a role in writing the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wisit Cheungpasitporn, MD, FACP, FASN, FAST, Associate Professor, Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. wcheungpasitporn@gmail.com
Received: January 30, 2021
Peer-review started: January 30, 2021
First decision: May 5, 2021
Revised: May 10, 2021
Accepted: June 16, 2021
Article in press: June 16, 2021
Published online: July 18, 2021
Processing time: 163 Days and 17.3 Hours
Peer-review started: January 30, 2021
First decision: May 5, 2021
Revised: May 10, 2021
Accepted: June 16, 2021
Article in press: June 16, 2021
Published online: July 18, 2021
Processing time: 163 Days and 17.3 Hours
Core Tip
Core Tip: Focal segmental glomerulosclerosis (FSGS) is associated with a high risk of recurrence after kidney transplantation. Plasmapheresis and/or rituximab has been used to prevent recurrence with conflicting results. This meta-analysis is among the first to report that the use of preemptive rituximab, either alone or in combination with plasmapheresis, or plasmapheresis alone, did not alter the recurrence risk of FSGS after kidney transplantation.